- Potential Use of Mycobacterium paragordonae for Antimycobacterial Drug Screening Systems
-
Ga-Yeong Cha , Hyejun Seo , Jaehun Oh , Byoung-Jun Kim , Bum-Joon Kim
-
J. Microbiol. 2023;61(1):121-129. Published online January 31, 2023
-
DOI: https://doi.org/10.1007/s12275-022-00009-1
-
-
1,073
View
-
3
Download
-
2
Web of Science
-
3
Crossref
-
 Abstract
 PDF
-
Our recent genome-based study indicated that Mycobacterium paragordonae (Mpg) has evolved to become more adapted to
an intracellular lifestyle within free-living environmental amoeba and its enhanced intracellular survival within Acanthamoeba
castellanii was also proved. Here, we sought to investigate potential use of Mpg for antimycobacterial drug screening
systems. Our data showed that Mpg is more susceptible to various antibiotics compared to the close species M. marinum
(Mmar) and M. gordonae, further supporting its intracellular lifestyle in environments, which would explain its protection
from environmental insults. In addition, we developed two bacterial whole-cell-based drug screening systems using a
recombinant Mpg stain harboring a luciferase reporter vector (rMpg-LuxG13): one for direct application to rMpg-LuxG13
and the other for drug screening via the interaction of rMpg-LuxG13 with A. castellanii. Direct application to rMpg-LuxG13
showed lower inhibitory concentration 50 (
IC50) values of rifampin, isoniazid, clarithromycin, and ciprofloxacin against
Mpg compared to Mmar. Application of drug screening system via the interaction of rMpg-LuxG13 with A. castellanii also
exhibited lower IC50
values for rifampin against Mpg compared to Mmar. In conclusion, our data indicate that Mpg is more
susceptible to various antibiotics than other strains. In addition, our data also demonstrate the feasibility of two whole cellbased
drug screening systems using rMpg-LuxG13 strain for the discovery of novel anti-mycobacterial drugs.
-
Citations
Citations to this article as recorded by  -
6-methylflavone exerts selective antimycobacterial activity with membrane energetics disruption and demonstrates therapeutic potential against
Mycobacterium abscessus
infection
Jaehun Oh, Jeong-Won Shin, Hyejun Seo, Hyung-Jun Kim, Nam-Jung Kim, Bum-Joon Kim, Prabagaran Narayanasamy
Microbiology Spectrum.2026;[Epub] CrossRef - Mycobacterium paragordonae: Insights into its Research Progress and Potential Applications
Hyejun Seo, Ju-Young Lee, Bum-Joon Kim
Journal of Bacteriology and Virology.2024; 54(4): 273. CrossRef - Protection against tuberculosis achieved by dissolving microneedle patches loaded with live Mycobacterium paragordonae in a BCG prime-boost strategy
Mi-Hyun Lee, Hyejun Seo, Moon-Su Lee, Byoung Jun Kim, Hye Lin Kim, Du Hyung Lee, Jaehun Oh, Ju Yeop Shin, Ju Young Jin, Do Hyeon Jeong, Bum-Joon Kim
Frontiers in Immunology.2023;[Epub] CrossRef
- Effect of amikacin on cell wall glycopeptidolipid synthesis in Mycobacterium abscessus
-
So-Young Lee , Hee-Youn Kim , Byoung-Jun Kim , Hong Kim , Seung-hyeok Seok , Bum-Joon Kim , Yoon-Hoh Kook
-
J. Microbiol. 2017;55(8):640-647. Published online July 28, 2017
-
DOI: https://doi.org/10.1007/s12275-017-6503-7
-
-
986
View
-
0
Download
-
7
Crossref
-
Abstract
PDF
-
Cultivation of the smooth colony Mycobacterium abscessus
at the sub-minimum inhibitory concentration (MIC) of amikacin
changed its growth pattern including its colony morphology
(smooth to rough) and cell arrangement (dispersed
to cord formation). In addition, reduced sliding motility and
biofilm formation were observed. The amount of glycogpetidolipid
(GPL) and mRNA expression of key genes involved
in GPL synthesis were decreased in the amikacin-treated M.
abscessus strain. An in vitro infection assay revealed that the
amikacin-treated smooth M. abscessus strain induced more
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) than that
of the smooth strain in murine macrophage cells. These results
suggest that long-term exposure to a low concentration of
amikacin causes a physical change in the cell wall which may
increase its virulence.
-
Citations
Citations to this article as recorded by - Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine
A. Calcagno, N. Coppola, L. Sarmati, M. Tadolini, R. Parrella, A. Matteelli, N. Riccardi, M. Trezzi, A. Di Biagio, V. Pirriatore, A. Russo, G. Gualano, E. Pontali, L. Surace, E. Falbo, J. Mencarini, F. Palmieri, A. Gori, M. Schiuma, G. Lapadula, D. Golett
Infection.2024; 52(3): 737. CrossRef - Moles of Molecules against Mycobacterium abscessus: A Review of Current Research
Mario Cocorullo, Christian Bettoni, Sara Foiadelli, Giovanni Stelitano
Future Pharmacology.2023; 3(3): 637. CrossRef - Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2017–2018
David J. Harvey
Mass Spectrometry Reviews.2023; 42(1): 227. CrossRef - The role of amikacin in the treatment of nontuberculous mycobacterial disease
Jelmer Raaijmakers, Jodie Anne Schildkraut, Wouter Hoefsloot, Jakko van Ingen
Expert Opinion on Pharmacotherapy.2021; 22(15): 1961. CrossRef - Integrated Quantitative Proteomics and Metabolome Profiling Reveal MSMEG_6171 Overexpression Perturbing Lipid Metabolism of Mycobacterium smegmatis Leading to Increased Vancomycin Resistance
Zhuhua Wu, Wenjing Wei, Ying Zhou, Huixin Guo, Jiao Zhao, Qinghua Liao, Liang Chen, Xiaoli Zhang, Lin Zhou
Frontiers in Microbiology.2020;[Epub] CrossRef - Glycopeptidolipids, a Double-Edged Sword of the Mycobacterium abscessus Complex
Ana Victoria Gutiérrez, Albertus Viljoen, Eric Ghigo, Jean-Louis Herrmann, Laurent Kremer
Frontiers in Microbiology.2018;[Epub] CrossRef - Role of the Mycobacterium marinum ESX-1 Secretion System in Sliding Motility and Biofilm Formation
Li-Yin Lai, Tzu-Lung Lin, Yi-Yin Chen, Pei-Fang Hsieh, Jin-Town Wang
Frontiers in Microbiology.2018;[Epub] CrossRef
|
MSK
